- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03991975
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
Phase Ib Study to Evaluate the Safety and Efficacy of TQB2450 (PD-L1 Antibody) Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jun Guo, Doctor
- Phone Number: 010-88196341
- Email: guoj307@126.com
Study Locations
-
-
Beijing
-
Beijin, Beijing, China, 100083
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Jun Guo, Doctor
- Phone Number: 010-88196341
- Email: guoj307@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.18 and 75 years; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Life expectancy ≥ 3 months.
2. Histologically or cytologically confirmed advanced acral malignant melanoma. 3. At least one measurable lesion. 4. Providing tumor specimen obtained by biopsy or surgical sample within 2 years.
5. Has received at least first-line treatment but appeared disease progression or intolerance.
6. The main organs function are normally, the following criteria are met:
- hemoglobin ≥ 90 g/L; neutrophils ≥ 1.5*10^9/L; platelets ≥ 100 x 10^9/ L;
- total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN ; serum creatinine ≤1╳ULN,creatinine clearance >50 umol/L ;
- INR, aPTT, PT≤1.5 x ULN;
- left ventricular ejection fraction (LVEF) ≥50%. 7. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
8.Understood and signed an informed consent form.
Exclusion Criteria:
- Prior therapy with VEGFR-target TKI included anlotinib or an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody ,or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its components.
- Has diagnosed and/or treated additional malignancy within 5 years prior to randomization. Exceptions include cured basal cell carcinoma of skin and carcinoma in situ of cervix.
- Has any active autoimmune disease or history of autoimmune disease.
- Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration.
- Has multiple factors affecting oral medication.
- Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
- Has any bleeding or bleeding events ≥ grade 3 or with unhealed wounds, ulcerative , or fractures within 4 weeks prior to the first administration.
- Has uncontrollable symptoms of brain metastasis, spinal cord compression, cancerous meningitis during screening within 8 weeks before first dose.
- Has received chemotherapy, surgery, radiotherapy, the last treatment from the first dose less than 4 weeks, or oral targeted drugs for less than 5 half-lives, or oral fluorouracil pyridine drugs for less than 14 days, mitomycin C and nitrosourea for less than 6 weeks.
- Has any serious and / or uncontrolled disease.
- Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first dose.
- Has received granulocyte colony stimulating factor(G -CSF),or Granulocyte macrophage colony stimulating factor (GM-CSF) within 4 weeks prior to first dose.
- According to the judgement of the researchers, there are other factors that may lead to the termination of the study. For example, other serious diseases including mental disorders need to be treated together, serious laboratory abnormalities, accompanied by family or social factors, which will affect the safety of the subjects, or the collection of data and samples.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anlotinib + TQB2450
TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
|
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
a multi-target receptor tyrosine kinase inhibitor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: up to 21 days
|
MTD defined as the highest dose level at which less than or equal to 2 of 6 subjects experience dose limiting toxicity (DLT)
|
up to 21 days
|
Recommended Phase II dose (RP2D)
Time Frame: up to 24 months
|
The RP2D defined as the lower dose level to MTD based on the safety profile
|
up to 24 months
|
Overall response rate (ORR)
Time Frame: up to 24 months
|
Percentage of subjects achieving complete response (CR) and partial response (PR)
|
up to 24 months
|
Dose limiting toxicity (DLT)
Time Frame: up to 21 days
|
Maximum tolerated dose(s) (MTD(s)) and/or recommended phase 2 dose (RP2D(s)) of Anlotinib and TQB2450 in advanced acral malignant melanoma patients, Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-21).
|
up to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate(DCR)
Time Frame: up to 24 months
|
Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)
|
up to 24 months
|
Progression-free survival (PFS)
Time Frame: up to 24 months
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause
|
up to 24 months
|
Overall survival (OS)
Time Frame: up to 24 months
|
OS defined as the time from randomization to death from any cause.
Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive
|
up to 24 months
|
Adverse Event
Time Frame: up to 24 months
|
Number of participants with adverse events
|
up to 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQB2450-Ib-09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Acral Malignant Melanoma
-
Qilu Hospital of Shandong UniversityNot yet recruitingLocally Advanced or Metastatic Acral Malignant MelanomaChina
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Pfizer; Beth Israel Deaconess Medical CenterCompletedMucosal Lentiginous Melanoma | Acral Lentiginous Malignant MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustCompletedA Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant MelanomaUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stage III Acral... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable MelanomaUnited States
-
Innovent Biologics (Suzhou) Co. Ltd.TerminatedAcral Melanoma That Has Been Removed by SurgeryChina
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
Zai Lab (Shanghai) Co., Ltd.TerminatedUnresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous MelanomaChina
Clinical Trials on TQB2450
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Oligometastatic Non-small Cell Lung CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingA Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical CancerChina
-
Jiangxi Provincial Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingDigestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell CarcinomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Solid TumorsChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingStage III Non-small-cell Lung CancerChina
-
Fudan UniversityRecruiting
-
Tianjin Medical University Cancer Institute and...Recruiting